High-dose carmustine and autologous bone marrow reinfusion in the treatment of refractory or relapsed small cell lung carcinoma
| Autor: | Keith A. Rodvold, Dean H. Kriesel, Darlene P. Koontz, Jane A. Gehlsen, Daniel A. Rushing, Mary C. Baldauf, Steven K. Broste, William R. Friedenberg |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Cancer Research
medicine.medical_specialty Vincristine Chemotherapy Carmustine Cyclophosphamide business.industry medicine.medical_treatment medicine.disease Small-cell carcinoma Gastroenterology Surgery Radiation therapy Oncology Refractory Internal medicine Medicine business Etoposide medicine.drug |
| Zdroj: | Cancer. 68:720-724 |
| ISSN: | 1097-0142 0008-543X |
| DOI: | 10.1002/1097-0142(19910815)68:4<720::aid-cncr2820680409>3.0.co;2-r |
| Popis: | Fourteen patients with small cell carcinoma of the lung in relapse or with disease refractory to chemotherapy were treated with carmustine (BCNU) at doses of 600 to 1000 mg/m2 intravenously followed by autologous bone marrow transplantation. All patients previously were treated with cyclophosphamide, doxorubicin, vincristine, and etoposide. Seven of the 14 patients responded to the high-dose BCNU (50% response with 95% confidence limits ranging from 23% to 77%). Three patients had a complete response, and four had a partial response. Regrowth of tumor occurred within 60 days of treatment in the responding patients. Death occurred in six patients before the recovery of the platelet count to 50,000 cells/microliters. Although the response rate was high, the toxicity was excessive. In the dosage range of 600 to 1000 mg/m2 in heavily pretreated patients, BCNU is not recommended, but additional investigation may be warranted in patients with central nervous system metastases who previously were treated with radiation therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text